New Silkroutes Group Limited (NSG) has signed a memorandum of understanding (MOU) with Huawei International to develop an artificial intelligence (AI) platform that can be used in genomics-driven healthcare.
Under the MOU, NSG and Huawei will explore a collaboration to use AI to establish breakthrough analyses into genomic data and develop predictive models for cancel and genomics.
Genomic medicine involves the study of a patient’s DNA and how the information can be used to improve clinical care through better diagnosis and personalised treatment.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)